Aceclofenac / Paracetamol /Chlorzoxazone
Non-opioid analgesic / antipyretic
What it is used for
Therapeutic use is agent- and indication-specific within the class (Non-opioid analgesic / antipyretic). Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC. Spastic Pain
Warnings
[From component Paracetamol] Risk of severe hepatotoxicity in overdose. Chronic high-dose use, malnutrition, enzyme-inducing drugs, and alcohol increase risk. Check total daily intake from all sources.
Possible side effects
[Aceclofenac] Dyspepsia, nausea, fluid retention, raised BP. Serious: peptic ulcer/bleed, AKI, heart failure exacerbation, severe skin reactions, bronchospasm, hepatitis (rare). [Paracetamol] Rare at therapeutic doses. Serious: acute liver failure in overdose, rare severe skin reactions (SJS/TEN/AGEP). [Chlorzoxazone] ADVERSE REACTIONS Chlorzoxazone containing products are usually well tolerated. It is possible in rare instances that chlorzoxazone may have been associated with gastrointestinal bleeding. Drowsiness, dizziness, lightheadedness, malaise, or over-stimulation may be noted by an occasional patient. Rarely, allergic type skin rashes, petechiae, or ecchymoses may develop during treatment. Angioneurotic edema or anaphylactic reactions are extremely rare. There is no evidence that the drug will cause renal damage. Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone. This finding is of no known clinical significance. To report SUSPECTED ADVERSE EVENTS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800- FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.
Storage
Store as labelled. Keep out of reach of children.
No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.